c-erbB-2 protein in serum of primary lung cancer patients

Rosa Filiberti, Paola Marroni, Michela Paganuzzi, Valeria Izzo, Paola Padovani, Mara Cafferata, Andrea Ardizzoni, Monica Neri, Luigi Raimondi, Riccardo Puntoni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We determined c-erbB-2 protein level in serum of 86 primary lung cancer patients (78 non-small cell lung carcinomas (NSCLC), 3 small cell carcinomas, 5 not histologically defined) and in 61 controls. Aim of this study was to evaluate the clinical usefulness of c-erbB-2 as marker for lung cancer diagnosis. The protein was measured with a commercially available sandwich enzyme immunoassay. Mean levels of c-erbB-2 were 72.8 ± 122.3 fmol/ml in lung cancers and 64.6 ± 17.5 fmol/ml in controls (P = 0.2). No association was found between c-erbB-2 levels and histotype, tumor stage, sex and smoking habits. Among NSCLC, only four patients showed a c-erbB-2 concentration higher than the selected cut-off value of 99.6 fmol/ml. Subjects with levels higher than the 75th percentile in tumors (73 fmol/ml) had a shorter median survival than those with lower levels (6.3 months versus 10.0 months, P = 0.003). Our results indicated that serum c-erbB-2 protein is not a reliable diagnostic marker. There is, however, a suggestion of a possible clinical usefulness in terms of survival prediction.

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalCancer Detection and Prevention
Volume26
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

ErbB-2 Receptor
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Serum
Small Cell Carcinoma
Survival
Immunoenzyme Techniques
Habits
Blood Proteins
Neoplasms
Smoking
Proteins

Keywords

  • c-erbB-2
  • Lung cancer
  • Oncoprotein
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Filiberti, R., Marroni, P., Paganuzzi, M., Izzo, V., Padovani, P., Cafferata, M., ... Puntoni, R. (2002). c-erbB-2 protein in serum of primary lung cancer patients. Cancer Detection and Prevention, 26(1), 64-68. https://doi.org/10.1016/S0361-090X(02)00014-4

c-erbB-2 protein in serum of primary lung cancer patients. / Filiberti, Rosa; Marroni, Paola; Paganuzzi, Michela; Izzo, Valeria; Padovani, Paola; Cafferata, Mara; Ardizzoni, Andrea; Neri, Monica; Raimondi, Luigi; Puntoni, Riccardo.

In: Cancer Detection and Prevention, Vol. 26, No. 1, 2002, p. 64-68.

Research output: Contribution to journalArticle

Filiberti, R, Marroni, P, Paganuzzi, M, Izzo, V, Padovani, P, Cafferata, M, Ardizzoni, A, Neri, M, Raimondi, L & Puntoni, R 2002, 'c-erbB-2 protein in serum of primary lung cancer patients', Cancer Detection and Prevention, vol. 26, no. 1, pp. 64-68. https://doi.org/10.1016/S0361-090X(02)00014-4
Filiberti, Rosa ; Marroni, Paola ; Paganuzzi, Michela ; Izzo, Valeria ; Padovani, Paola ; Cafferata, Mara ; Ardizzoni, Andrea ; Neri, Monica ; Raimondi, Luigi ; Puntoni, Riccardo. / c-erbB-2 protein in serum of primary lung cancer patients. In: Cancer Detection and Prevention. 2002 ; Vol. 26, No. 1. pp. 64-68.
@article{45d49dd2473c4d618bcc53ff5df1a9a7,
title = "c-erbB-2 protein in serum of primary lung cancer patients",
abstract = "We determined c-erbB-2 protein level in serum of 86 primary lung cancer patients (78 non-small cell lung carcinomas (NSCLC), 3 small cell carcinomas, 5 not histologically defined) and in 61 controls. Aim of this study was to evaluate the clinical usefulness of c-erbB-2 as marker for lung cancer diagnosis. The protein was measured with a commercially available sandwich enzyme immunoassay. Mean levels of c-erbB-2 were 72.8 ± 122.3 fmol/ml in lung cancers and 64.6 ± 17.5 fmol/ml in controls (P = 0.2). No association was found between c-erbB-2 levels and histotype, tumor stage, sex and smoking habits. Among NSCLC, only four patients showed a c-erbB-2 concentration higher than the selected cut-off value of 99.6 fmol/ml. Subjects with levels higher than the 75th percentile in tumors (73 fmol/ml) had a shorter median survival than those with lower levels (6.3 months versus 10.0 months, P = 0.003). Our results indicated that serum c-erbB-2 protein is not a reliable diagnostic marker. There is, however, a suggestion of a possible clinical usefulness in terms of survival prediction.",
keywords = "c-erbB-2, Lung cancer, Oncoprotein, Tumor marker",
author = "Rosa Filiberti and Paola Marroni and Michela Paganuzzi and Valeria Izzo and Paola Padovani and Mara Cafferata and Andrea Ardizzoni and Monica Neri and Luigi Raimondi and Riccardo Puntoni",
year = "2002",
doi = "10.1016/S0361-090X(02)00014-4",
language = "English",
volume = "26",
pages = "64--68",
journal = "Cancer Detection and Prevention",
issn = "0361-090X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - c-erbB-2 protein in serum of primary lung cancer patients

AU - Filiberti, Rosa

AU - Marroni, Paola

AU - Paganuzzi, Michela

AU - Izzo, Valeria

AU - Padovani, Paola

AU - Cafferata, Mara

AU - Ardizzoni, Andrea

AU - Neri, Monica

AU - Raimondi, Luigi

AU - Puntoni, Riccardo

PY - 2002

Y1 - 2002

N2 - We determined c-erbB-2 protein level in serum of 86 primary lung cancer patients (78 non-small cell lung carcinomas (NSCLC), 3 small cell carcinomas, 5 not histologically defined) and in 61 controls. Aim of this study was to evaluate the clinical usefulness of c-erbB-2 as marker for lung cancer diagnosis. The protein was measured with a commercially available sandwich enzyme immunoassay. Mean levels of c-erbB-2 were 72.8 ± 122.3 fmol/ml in lung cancers and 64.6 ± 17.5 fmol/ml in controls (P = 0.2). No association was found between c-erbB-2 levels and histotype, tumor stage, sex and smoking habits. Among NSCLC, only four patients showed a c-erbB-2 concentration higher than the selected cut-off value of 99.6 fmol/ml. Subjects with levels higher than the 75th percentile in tumors (73 fmol/ml) had a shorter median survival than those with lower levels (6.3 months versus 10.0 months, P = 0.003). Our results indicated that serum c-erbB-2 protein is not a reliable diagnostic marker. There is, however, a suggestion of a possible clinical usefulness in terms of survival prediction.

AB - We determined c-erbB-2 protein level in serum of 86 primary lung cancer patients (78 non-small cell lung carcinomas (NSCLC), 3 small cell carcinomas, 5 not histologically defined) and in 61 controls. Aim of this study was to evaluate the clinical usefulness of c-erbB-2 as marker for lung cancer diagnosis. The protein was measured with a commercially available sandwich enzyme immunoassay. Mean levels of c-erbB-2 were 72.8 ± 122.3 fmol/ml in lung cancers and 64.6 ± 17.5 fmol/ml in controls (P = 0.2). No association was found between c-erbB-2 levels and histotype, tumor stage, sex and smoking habits. Among NSCLC, only four patients showed a c-erbB-2 concentration higher than the selected cut-off value of 99.6 fmol/ml. Subjects with levels higher than the 75th percentile in tumors (73 fmol/ml) had a shorter median survival than those with lower levels (6.3 months versus 10.0 months, P = 0.003). Our results indicated that serum c-erbB-2 protein is not a reliable diagnostic marker. There is, however, a suggestion of a possible clinical usefulness in terms of survival prediction.

KW - c-erbB-2

KW - Lung cancer

KW - Oncoprotein

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0036951944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036951944&partnerID=8YFLogxK

U2 - 10.1016/S0361-090X(02)00014-4

DO - 10.1016/S0361-090X(02)00014-4

M3 - Article

C2 - 12088205

AN - SCOPUS:0036951944

VL - 26

SP - 64

EP - 68

JO - Cancer Detection and Prevention

JF - Cancer Detection and Prevention

SN - 0361-090X

IS - 1

ER -